Batsheva Kerem, Ph.D.
Professor Batsheva Kerem, Ph.D., received a B.Sc from the Hebrew University in 1979, received a Ph.D. there in 1986, and then completed a three-year post doctorate fellowship in the Department of Genetics, the Research Institute of the Hospital for Sick Children, Toronto, Canada. During her post doctorate fellowship, Prof. Kerem was part of the group that identified the cystic fibrosis gene. After returning to Israel in 1990, she established a research group. She currently is a Full Professor in the Department of Genetics, the Life Sciences Institute of the Hebrew University.
Her research group studies the molecular bases of diseases. Prof. Kerem's main interest is in understanding the molecular basis of disease variability among patients carrying the same genetic differences. This includes genetic modifiers and environmental factors. Her recent studies are focused on cystic fibrosis, asthma, allergy, and cancer. In cystic fibrosis, she studies modifier genes that modulate disease severity among patients carrying "splicing" or "stop" mutations. In cancer, she studies the role of specific regions defined as fragile sites in underlying chromosomal instability in cancer cells.
Professor Eitan Kerem, M.D., graduated from the Hebrew University Hadassah Medical School in 1982, completed a pediatric residency, took a three-year fellowship in Pediatric Pulmonology at the Chest Division, the Hospital for Sick Children, Toronto, Canada, and returned to Israel in 1990. He is currently Associate Professor in Pediatrics at the Hebrew University, Hadassah Medical School, and Head of the Department of Pediatrics at Hadassah University Hospital, Jerusalem.
His research concerns the association between genotype and phenotype in respiratory diseases and the interaction of environmental factors with genetic diseases and their influence on disease severity. His recent studies focused on the genetic markers of asthma and allergy in closed populations, and disease variability in closed populations exposed to different environments. His studies on cystic fibrosis examine prognostic factors for disease severity and prediction of mortality, molecular mechanisms involved in disease variability, and development of new mutation-specific pharmacological therapies to correct the basic defects in cystic fibrosis.